AMV-602

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug NameAMV-602
Drug Alias NameRespiVacRSV vaccine (recombinant Sendai-paramyxovirus) (AmVac)AMV-602AMV-603AMV-601
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Recombinant vector vaccine
Mechanisms of ActionImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsRespiratory Syncytial Virus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryItalySwitzerland
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAmVac AG
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAmVac AG
Active IndicationsN/A
Inactive IndicationsRespiratory Syncytial Virus Infections

Other Information

ATC CodeN/A
Related LinksN/A